Respirerx Pharmaceuticals Inc.
Publicly observedGlen Rock, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Glen Rock | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Respirerx Pharmaceuticals Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | HWS8C3MQDTH7 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant23 Sept 2025Publicly observed
NIH SBIR/STTR award: Development of a novel, preferring potentiator of GABAA receptor for treatment of epilepsy
USD 1,499,869.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)
- Grant23 Sept 2025Publicly observed
NIH SBIR/STTR award: Development of a novel, preferring potentiator of GABAA receptor for treatment of epilepsy
USD 1,499,869.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.